Does Myrcene Help THC Cross the Blood-Brain Barrier?

Last updated on September 22, 2026 · Originally published April 1, 2019

A remarkably persistent cannabis claim says that myrcene strengthens the so-called entourage effect by making the blood–brain barrier (BBB) more permeable, allowing more THC to reach the brain. Of all the terpenes, β-myrcene – a linear monoterpene – is the compound most often credited with this supposed ability.

Myrcene takes its name from the plant genus Myrcia. Myrcia sphaerocarpa, now generally treated as a synonym of Myrcia multiflora, is a Brazilian shrub traditionally used for conditions including diabetes and diarrhea. [1] Myrcene is one of the most abundant monoterpenes in many cannabis cultivars [2] – at levels that vary with the cultivar and how it was grown. Higher myrcene concentrations are alleged to help cannabinoids enter the brain more readily, providing a convenient explanation for reports that whole-plant cannabis and full-spectrum extracts can feel different from isolated cannabinoids.

Figure 1. Chemical structure of β-myrcene, a linear (non-cyclic) monoterpene.

While this provides a neat and testable hypothesis, it remains unsupported by direct experimental evidence.

We Re-Ran the Search in 2026

That was true when we first published this article in 2019. Because claims about an absence of evidence deserve to be rechecked, we searched the literature again in September 2026. We again found no peer-reviewed experiment directly testing or demonstrating that myrcene makes the BBB more permeable to THC or other cannabinoids.

Precision matters here because two propositions are routinely blended together. Whether myrcene itself can reach the brain is one question. Whether it alters the barrier so that more THC enters is another. Evidence for the first would not establish the second – and the second is the mechanism behind the popular claim.

The claim has nevertheless entered review literature. A 2024 review, for example, states that terpenes can increase BBB permeability, but the references attached to that statement do not report an experiment directly testing whether myrcene increases THC transport across the barrier. [7] Repetition has given the proposition the appearance of scientific support, but not the missing experiment.

Borneol: Where the Preclinical BBB Evidence Exists

Borneol, a bicyclic monoterpenoid alcohol with a camphoraceous scent, has something myrcene does not: direct experimental evidence of BBB modulation. In a rat study, borneol increased the delivery of a marker compound to parts of the brain and produced changes involving tight-junction proteins and drug-transport mechanisms. [4] Subsequent reviews have examined this preclinical evidence and its possible drug-delivery applications. [3,5] That does not establish that dietary or cannabis-level borneol opens the human BBB, but it provides a genuine experimental foundation for further research.

A 2023 narrative review describes an apparently bidirectional pattern in preclinical models. Under some conditions, borneol increased the brain delivery of co-administered compounds; in animal models of ischemic stroke, it sometimes reduced pathological BBB leakage and helped preserve barrier function. [6] Real pharmacology tends to look like this – conditional, mechanism-specific, and dose-dependent. It looks nothing like “eat a mango, open your brain.”

This is why scientific-sounding claims require scrutiny, especially when they spread through repetition. A plausible statement can be distorted, embellished, or treated as established fact without the experiment needed to support it. As for the famous corollary – that eating a ripe mango before consuming cannabis makes you higher – eating mango may be innocuous for most people, but it has not been demonstrated to increase THC delivery to the brain.

The lesson is larger than myrcene. A plausible mechanism can become common knowledge through repetition long before anyone performs the experiment needed to establish it. Ask not only whether a claim has a citation, but whether the cited study actually tested the claim.

As of September 2026, we could find no such study for myrcene and THC transport across the BBB. If that experiment is published – or if we have missed it – send it our way. Seven years later, the search remains open.

References

1. Ulbricht C. Focus: Diabetes. Journal of Dietary Supplements. 2011;8(3):239–256. doi:10.3109/19390211.2011.597975
2. Fischedick JT, Hazekamp A, Erkelens T, Choi YH, Verpoorte R. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry. 2010;71(17-18):2058–2073.
3. Zhang QL, Fu BM, Zhang ZJ. Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability. Drug Delivery. 2017;24(1):1037–1044. doi:10.1080/10717544.2017.1346002
4. Yu B, et al. The mechanism of the opening of the blood–brain barrier by borneol: A pharmacodynamics and pharmacokinetics combination study. Journal of Ethnopharmacology. 2013;150(3):1096–1108.
5. Wu T, Zhang A, Lu H, Cheng Q. The Role and Mechanism of Borneol to Open the Blood-Brain Barrier. Integrative Cancer Therapies. 2018;17(3):806–812. doi:10.1177/1534735418767553
6. Tan X, Zhang K, Shi W, Tang Z. Research progress on the regulation and mechanism of borneol on the blood-brain barrier in pathological states: a narrative review focused on ischemic stroke and cerebral glioma. Translational Cancer Research. 2023;12(11):3198–3209. doi:10.21037/tcr-23-1487
7. André R, Gomes AP, Pereira-Leite C, et al. The Entourage Effect in Cannabis Medicinal Products: A Comprehensive Review. Pharmaceuticals. 2024;17(11):1543. doi:10.3390/ph17111543

Last updated September 2026 · Originally published April 1, 2019.